Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),
Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities
Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging